1. Scrip
  2. >>Focus On Asia
  3. >>China

Chinese API Imports Eclipse Indian Plants

 
• By Anju Ghangurde

Indian firms have underscored growing concern around an ''over-dependence'' on Chinese active pharmaceutical ingredient (API) imports and the potentially crippling effect these could have on India's own essential drug supplies, should there be any turbulence in Indo-China relations.

A white paper by the Indian Drug Manufacturers Association (IDMA) refers to how imports of APIs and advanced intermediates have grown at a compound annual growth rate (CAGR) of 18% over the past decade from $800m in 2004 to $3.4bn currently, with China estimated to contribute around 58% of these imports by value.

“'China's contribution to India's total imports increased by 19% from 2004 to 2007 and has been stable since. In volume terms, the picture is starker, with China's share of imports...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Hengrui Set For Biggest Biopharma IPO So Far This Year

 
• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

China Biopharma Podcast

 
• By Dexter Jie Yan and Xu Hu

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

More from Focus On Asia